OncoMatch/Clinical Trials/NCT06235216
Sacituzumab govitEcan in THYroid Cancers
Is NCT06235216 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Sacituzumab govitecan for differentiated thyroid cancer.
Treatment: Sacituzumab govitecan — SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC). The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Thyroid Gland Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy (sorafenib, lenvatinib, cabozantinib) — differentiated thyroid cancer (cohort A)
Cohort A: Patients must have experienced progression on at least one previous treatment line with approved systemic therapies (Sorafenib, Lenvatinib or Cabozantinib) and a maximum of 3 prior systemic therapies.
Cannot have received: topoisomerase 1 inhibitor
Patient has previously received topoisomerase 1 inhibitors.
Lab requirements
Blood counts
Neutrophil count (ANC) ≥ 1,500/mm3; Platelet count ≥ 100 × 10^9/L; Hemoglobin ≥ 9 g/dL
Kidney function
Creatinine clearance (CrCl) ≥ 60 mL/min as estimated by the Cockroft-Gault formula or as measured by 24 hour urine collection (GFR can also be used instead of CrCl)
Liver function
Serum bilirubin ≤ 1.5 × ULN (patients with Gilbert's disease are excluded); ALT and AST ≤ 2.5 × ULN or ≤ 5 × ULN for patients with liver metastases; serum albumin > 3 g/dL
Cardiac function
No myocardial infarction or unstable angina pectoris within 6 months; no history of serious ventricular arrhythmia, high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for well-controlled atrial fibrillation); no history of QT interval prolongation; NYHA class III or greater congestive heart failure or LVEF < 40% excluded
The following baseline laboratory data without transfusional support: Neutrophil count (ANC) ≥ 1,500/mm3. Platelet count ≥ 100 × 10^9/L. Hemoglobin ≥ 9 g/dL. Serum bilirubin ≤ 1.5 × ULN. Serum albumin > 3 g/dL. Creatinine clearance (CrCl) ≥ 60 mL/min. ALT and AST ≤ 2.5 × ULN or ≤ 5 × ULN for patients with liver metastases. Cardiac exclusion criteria: see exclusion 6.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06235216 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior topoisomerase 1 inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages